Stimulatory Effect of Allantoin on Imidazoline I₁ Receptors in Animal and Cell Line

Abstract

Allantoin is known as the agonist of imidazoline receptor, especially the I₂ subtype. Effect of allantoin on imidazoline I₁ receptor (I₁R) relating to reduction of blood pressure and its merit in steatosis are still obscure. Also, farnesoid X receptor (FXR) plays an important role in lipid homeostasis related to I₁R activation. Thus, we administered allantoin into high fat diet (HFD)-fed mice showing hypertriglyceridemia and hypercholesterolemia. Allantoin significantly improved hyperlipidemia in HFD mice after 4 weeks of administration. Pretreatment with efaroxan, at a dose sufficient to inhibit I₁R activation, attenuated the action of allantoin. In addition, in cultured HepG2 cells, allantoin increased the expression of farnesoid X receptor (FXR). The allantoin-induced FXR expression was blocked by efaroxan. Similar changes were observed in the expressions of FXR-targeted genes. Otherwise, allantoin also lowered systolic blood pressure (SBP) in HFD mice that can be blocked by efaroxan. Taken together, allantoin has an ability to activate I₁R for improvement of metabolic disorders.

Key words

allantoin - blood pressure - efaroxan - farnesoid X receptor (FXR) - imidazoline receptor - steatosis

• References

• 1 Sagara K, Ojima M, Suto K, Yoshida T. Quantitative determination of allantoin in Dioscorea rhizome and an Oriental pharmaceutical preparation, hachimi-gan, by high-performance liquid chromatography. Planta Med 1989; 55: 93
• 2 Lee MY, Lee NH, Jung D, Lee JA, Seo CS, Lee H, Kim JH, Shin HK. Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma. Int Immunopharmacol 2010; 10: 474-480
• 3 Shi YC, Liao JW, Pan TM. Antihypertriglyceridemia and anti-inflammatory activities of monascus-fermented dioscorea in streptozotocin-induced diabetic rats. Exp Diabetes Res 2011; 2011: 710635
• 4 Chang WC, Yu YM, Wu CH, Tseng YH, Wu KY. Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. Can J Physiol Pharmacol 2005; 83: 423-430
• 5 Gao X, Li B, Jiang H, Liu F, Xu D, Liu Z. Dioscorea opposita reverses dexamethasone induced insulin resistance. Fitoterapia 2007; 78: 12-15
• 6 Hsu JH, Wu YC, Liu IM, Cheng JT. Dioscorea as the principal herb of Die-Huang-Wan, a widely used herbal mixture in China, for improvement of insulin resistance in fructose-rich chow-fed rats. J Ethnopharmacol 2007; 112: 577-584
• 7 Shujun W, Jinglin Y, Wenyuan G, Hongyan L, Peigen X. New starches from traditional Chinese medicine (TCM) – Chinese yam (Dioscorea opposita Thunb.) cultivars. Carbohydr Res 2006; 341: 289-293
• 8 Niu CS, Chen W, Wu HT, Cheng KC, Wen YJ, Lin KC, Cheng JT. Decrease of plasma glucose by allantoin, an active principle of yam ( Dioscorea spp.), in streptozotocin-induced diabetic rats. J Agric Food Chem 58: 12031-12035
• 9 Aje TO, Miller M. Cardiovascular disease: A global problem extending into the developing world. World J Cardiol 2009; 1: 3-10
• 10 McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 2008; 10: 386-390
• 11 Lin KC, Yeh LR, Chen LJ, Wen YJ, Cheng KC, Cheng JT. Plasma Glucose-lowering Action of Allantoin is Induced by Activation of Imidazoline I-2 Receptors in Streptozotocin-induced Diabetic Rats. Horm Metab Res 2012; 44: 41-46
• 12 Kaliszan W, Petrusewicz J, Kaliszan R. Imidazoline receptors in relaxation of acetylcholine-constricted isolated rat jejunum. Pharmacol Rep 2006; 58: 700-710
• 13 Morgan NG, Chan SL. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?. Curr Pharm Des 2001; 7: 1413-1431
• 14 Prichard BN, Graham BR. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Drugs Aging 2000; 17: 133-159
• 15 Niu CS, Wu HT, Cheng KC, Lin KC, Chen CT, Cheng JT. A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice. Horm Metab Res 2011; 43: 458-463
• 16 Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 300-312
• 17 Chang CH, Tsao CW, Huang SY, Cheng JT. Activation of imidazoline I(2B) receptors by guanidine to increase glucose uptake in skeletal muscle of rats. Neurosci Lett 2009; 467: 147-149
• 18 Chen MF, Yang TT, Yeh LR, Chung HH, Wen YJ, Lee WJ, Cheng JT. Activation of Imidazoline I-2B Receptors by Allantoin to Increase Glucose Uptake into C2C12 Cells. Horm Metab Res 2012; 44: 268-272
• 19 Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP. ‘Seeing through a glass darkly’: casting light on imidazoline ‘I’ sites. Trends Pharmacol Sci 1998; 19: 381-390
• 20 Wang SR, Pessah M, Infante J, Catala D, Salvat C, Infante R. Lipid and lipoprotein metabolism in Hep G2 cells. Biochim Biophys Acta 1988; 961: 351-363
• 21 Chapados NA, Seelaender M, Levy E, Lavoie JM. Effects of exercise training on hepatic microsomal triglyceride transfer protein content in rats. Horm Metab Res 2009; 41: 287-293
• 22 Ji W, Gong BQ. Hypolipidemic effects and mechanisms of Panax notoginseng on lipid profile in hyperlipidemic rats. J Ethnopharmacol 2007; 113: 318-324
• 23 Yang PS, Wu HT, Chung HH, Chen CT, Chi CW, Yeh CH, Cheng JT. Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 51-56
• 24 Cayla C, Schaak S, Roquelaine C, Gales C, Quinchon F, Paris H. Homologous regulation of the alpha2C-adrenoceptor subtype in human hepatocarcinoma, HepG2. Br J Pharmacol 1999; 126: 69-78
• 25 Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol 2008; 93: 27-42
• 26 Sharma R, Long A, Gilmer JF. Advances in bile acid medicinal chemistry. Curr Med Chem 2011; 18: 4029-4052
• 27 Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25: 2020-2030
• 28 Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28: 220-224
• 29 Lu TT, Repa JJ, Mangelsdorf DJ. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 2001; 276: 37735-37738
• 30 Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003; 278: 104-110
• 31 Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 2009; 296: G543-G552
• 32 Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009; 328: 116-122
• 33 Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131
• 34 Shimano H. Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm 2002; 65: 167-194
• 35 Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418
• 36 Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 1990; 265: 4266-4272
• 37 Murdoch SJ, Breckenridge WC. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL. Atherosclerosis 1995; 118: 193-212
• 38 Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995; 95: 705-712
• 39 Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, Gonzalez FJ, Willson TM, Edwards PA. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001; 15: 1720-1728
• 40 Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003; 125: 544-555
• 41 Blacklow SC. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Curr Opin Struct Biol 2007; 17: 419-426
• 42 Ma PT, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986; 83: 8370-8374
• 43 Soares EA, Nakagaki WR, Garcia JA, Camilli JA. Effect of hyperlipidemia on femoral biomechanics and morphology in low-density lipoprotein receptor gene knockout mice. J Bone Miner Metab 2012; Jan 14